BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shoham T, Sternberg D, Brosh N, Krupsky M, Barda-saad M, Zipori D. The promotion of plasmacytoma tumor growth by mesenchymal stroma is antagonized by basic fibroblast growth factor induced activin A. Leukemia 2001;15:1102-10. [DOI: 10.1038/sj.leu.2402145] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Parameswaran R, Morad V, Laronne A, Rousso-noori L, Shani N, Naffar-abu-amara S, Zipori D. Targeting the Bone Marrow with Activin A-Overexpressing Embryonic Multipotent Stromal Cells Specifically Modifies B Lymphopoiesis. Stem Cells and Development 2008;17:93-106. [DOI: 10.1089/scd.2007.0099] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
2 Shav‐tal Y, Zipori D. The Role of Activin A in Regulation of Hemopoiesis. Stem Cells 2002;20:493-500. [DOI: 10.1634/stemcells.20-6-493] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 2.6] [Reference Citation Analysis]
3 Barda-saad M, Shav-tal Y, Rozenszajn AL, Cohen M, Zauberman A, Karmazyn A, Parameswaran R, Schori H, Ashush H, Ben-nun A, Zipori D. The mesenchyme expresses T cell receptor mRNAs: relevance to cell growth control. Oncogene 2002;21:2029-36. [DOI: 10.1038/sj.onc.1205269] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
4 Zipori D. The mesenchyme in cancer therapy as a target tumor component, effector cell modality and cytokine expression vehicle. Cancer Metastasis Rev 2006;25:459-67. [DOI: 10.1007/s10555-006-9012-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
5 Zipori D. The hemopoietic stem cell niche versus the microenvironment of the multiple myeloma-tumor initiating cell. Cancer Microenviron. 2010;3:15-28. [PMID: 21209772 DOI: 10.1007/s12307-009-0034-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
6 Antsiferova M, Werner S. The bright and the dark sides of activin in wound healing and cancer. J Cell Sci 2012;125:3929-37. [PMID: 22991378 DOI: 10.1242/jcs.094789] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 6.8] [Reference Citation Analysis]
7 Shoham T, Parameswaran R, Shav-tal Y, Barda-saad M, Zipori D. The Mesenchymal Stroma Negatively Regulates B Cell Lymphopoiesis through the Expression of Activin A. Annals of the New York Academy of Sciences 2003;996:245-60. [DOI: 10.1111/j.1749-6632.2003.tb03253.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
8 Biber G, Ben-Shmuel A, Sabag B, Barda-Saad M. Actin regulators in cancer progression and metastases: From structure and function to cytoskeletal dynamics. Int Rev Cell Mol Biol 2020;356:131-96. [PMID: 33066873 DOI: 10.1016/bs.ircmb.2020.05.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Pevsner-fischer M, Levin S, Zipori D. The Origins of Mesenchymal Stromal Cell Heterogeneity. Stem Cell Rev and Rep 2011;7:560-8. [DOI: 10.1007/s12015-011-9229-7] [Cited by in Crossref: 170] [Cited by in F6Publishing: 154] [Article Influence: 15.5] [Reference Citation Analysis]